You are here: Welcome to the MPKB » Welcome to the MPKB » Marshall Protocol
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:mp [03.13.2019] – [Data] sallieqhome:mp [05.26.2019] – [Response in 5 diagnoses] sallieq
Line 250: Line 250:
 Olmesartan will need to be [[home:mp:break:olmesartan#stopping_olmesartan|weaned very gradually]]. Note that the immune response may remain activated for a period of time even after discontinuing olmesartan. Patients who stop olmesartan are terminating their recovery. Olmesartan will need to be [[home:mp:break:olmesartan#stopping_olmesartan|weaned very gradually]]. Note that the immune response may remain activated for a period of time even after discontinuing olmesartan. Patients who stop olmesartan are terminating their recovery.
  
 +
 +{{tag>MP summary}}  
 ===== Data ===== ===== Data =====
  
Line 256: Line 258:
 [[home:food:aim_health:aging|Olmesartan research]] [[home:food:aim_health:aging|Olmesartan research]]
  
 +==== Recovery figures ====
 +
 + TOTALS: 864 members;573 report success; 119 report no success; and for 172 results are not clear.
 +
 +SUCCESS RATES: Over all success rate 66.32% Over all unsuccessful 13.77% Over all unsure 19.91%
 +
 +Sarcoidosis success 75.8%
 +
 +Chronic Fatigue Syndrome success 60.1%
 +
 +Lyme disease success 66.9%
 +
 +Rheumatoid arthritis success 69.2%
 +
 +Fibromyalgia success 64.2%
 +
 +All Other Th1 disease success 59.8% 
 ===== Notes and comments ===== ===== Notes and comments =====
  
home/mp.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.